Cargando…
Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives
Head and neck cancer (HNC) is a common malignant tumor, but traditional therapeutic methods have unsatisfactory curative effects and many complications occur. Hence, there is an urgent need to develop therapeutic methods that can elicit curative effects as well as low toxic and few side effects. Wit...
Autores principales: | Ran, Xiongwen, Yang, Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501623/ https://www.ncbi.nlm.nih.gov/pubmed/28721019 http://dx.doi.org/10.2147/DDDT.S140687 |
Ejemplares similares
-
Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
por: Yang, Bo, et al.
Publicado: (2018) -
Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022) -
The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
por: Qiao, Xin-wei, et al.
Publicado: (2020) -
Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment
por: Serratì, Simona, et al.
Publicado: (2023) -
Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
por: Yang, Zhengyang, et al.
Publicado: (2022)